- Featured Product
- KD/KO Validated
SLC1A5/ASCT2 Polyclonal antibody
SLC1A5/ASCT2 Polyclonal Antibody for FC, IF/ICC,IF-P, IHC, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse
Applications
FC, IF/ICC,IF-P, IHC, WB, ELISA
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive WB detected in | HeLa cells |
| Positive IHC detected in | human colon cancer tissue, human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF detected in | mouse small intestine tissue, HEK-293 cells |
| Positive FC detected in | HeLa cells |
Planning an IF experiment? We recommend our CoraLite® Plus 488 conjugated versions of this antibody.
推荐稀释比
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:16000 |
| Immunohistochemistry (IHC) | IHC : 1:400-1:1600 |
| Immunofluorescence (IF) | IF : 1:50-1:500 |
| Flow Cytometry (FC) | FC : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
20350-1-AP targets SLC1A5/ASCT2 in WB, IF, FC, IHC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Applications | FC, IF/ICC,IF-P, IHC, WB, ELISA |
| Cited Applications | WB, IF, IHC |
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse |
| Immunogen | SLC1A5/ASCT2 fusion protein Ag14182 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | solute carrier family 1 (neutral amino acid transporter), member 5 |
| Synonyms | AAAT, ASCT2, ATB(0), ATBO, Baboon M7 virus receptor, M7V1, M7VS1, R16, RDR, RDRC, SLC1A5 |
| Calculated Molecular Weight | 541 aa, 57 kDa |
| Observed Molecular Weight | 55-70 kDa |
| GenBank Accession Number | BC000062 |
| Gene Symbol | SLC1A5 |
| Gene ID (NCBI) | 6510 |
| RRID | AB_2878679 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q15758 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
SLC1A5 (Solute Carrier Family 1, member 5), also named as ASCT2, a major glutamine transporter belonging to the SLC1 family and localized in the plasma membrane of several body districts. Consistent with the functions exerted by glutamine, SLC1A5 is involved in uptake of essential amino acids, activation of mTORC1 and glutamine-dependent tumor cell survival and growth. SLC1A5 is highly expressed in various malignancies and plays a critical role in the transformation, growth and survival of cancer cells (PMID: 30234109). High SLC1A5 expression is associated with poor prognosis in clear-cell renal cell carcinoma (PMID: 26599282).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| IHC protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| IF protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| FC protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Theranostics PPAR-γ integrates obesity and adipocyte clock through epigenetic regulation of Bmal1. | ||
Cell Biol Toxicol Degradation of HIF-1α induced by curcumol blocks glutaminolysis and inhibits epithelial-mesenchymal transition and invasion in colorectal cancer cells. | ||
Aging (Albany NY) The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma. | ||
Mol Ther Oncolytics Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment.
| ||
Mol Ther Oncolytics Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma. | ||
